Reviewing Translate Bio Inc. (TBIO)’s and Sierra Oncology Inc. (NASDAQ:SRRA)’s results

Translate Bio Inc. (NASDAQ:TBIO) and Sierra Oncology Inc. (NASDAQ:SRRA) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Translate Bio Inc. N/A 1940.35 108.27M -3.06 0.00
Sierra Oncology Inc. N/A 0.00 49.65M -0.63 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Translate Bio Inc. and Sierra Oncology Inc.

Profitability

Table 2 shows Translate Bio Inc. and Sierra Oncology Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Translate Bio Inc. 0.00% 208.7% -52.9%
Sierra Oncology Inc. 0.00% -43.8% -40.8%

Liquidity

Translate Bio Inc. has a Current Ratio of 16.7 and a Quick Ratio of 16.7. Competitively, Sierra Oncology Inc.’s Current Ratio is 14.7 and has 14.7 Quick Ratio. Translate Bio Inc.’s better ability to pay short and long-term obligations than Sierra Oncology Inc.

Analyst Ratings

In next table is shown Translate Bio Inc. and Sierra Oncology Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Translate Bio Inc. 0 0 2 3.00
Sierra Oncology Inc. 0 0 0 0.00

Translate Bio Inc.’s consensus target price is $23, while its potential upside is 124.83%.

Institutional and Insider Ownership

Translate Bio Inc. and Sierra Oncology Inc. has shares held by institutional investors as follows: 49.9% and 63.4%. About 19.6% of Translate Bio Inc.’s share are held by insiders. Comparatively, Sierra Oncology Inc. has 0.96% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Translate Bio Inc. 17.7% 26.07% -26.26% 0% 0% -26.13%
Sierra Oncology Inc. -6.75% -8.98% -18.28% -52.35% -46.48% -59.25%

For the past year Translate Bio Inc.’s stock price has smaller decline than Sierra Oncology Inc.

Summary

Translate Bio Inc. beats Sierra Oncology Inc. on 5 of the 8 factors.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.